MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-07-2023
Eargo EPS Ratio 2011-2026 | EAR
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.7 | -81.1 | -76.1 | -173 | -150 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -39.7 | -173 | -104 |
Quarterly EPS Ratio Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.83 | -1.21 | -1.06 | - | -25.7 | -16.5 | -15.6 | - | -2.02 | -0.5 | -0.36 | - | -57.7 | -23.7 | -43.8 | - | -46.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.36 | -57.7 | -18.1 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Medical devices industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
-0.52 | $ 13.17 | 0.46 % | $ 1.78 B |  USA |
 |
BIOLASE
BIOL
|
-29.4 | - | -13.19 % | $ 166 K | USA |
 |
Allied Healthcare Products
AHPI
|
-0.48 | - | 3.58 % | $ 2.21 M | USA |
 |
Delcath Systems
DCTH
|
0.08 | $ 10.8 | 4.05 % | $ 387 M | USA |
 |
Apollo Endosurgery
APEN
|
-0.98 | - | - | $ 475 M | USA |
 |
Second Sight Medical Products
EYES
|
-0.43 | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
0.89 | $ 25.6 | -0.43 % | $ 216 M | USA |
 |
Avinger
AVGR
|
-23.3 | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-1.28 | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-0.51 | $ 3.47 | 4.52 % | $ 130 M |  France |
 |
Aziyo Biologics
AZYO
|
1.29 | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-9.65 | - | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
-14.6 | $ 2.12 | 3.92 % | $ 1.29 M | USA |
 |
Inspire Medical Systems
INSP
|
4.95 | $ 56.7 | 1.0 % | $ 1.67 B | USA |
 |
Conformis
CFMS
|
-6.99 | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
-4.45 | $ 61.0 | 1.5 % | $ 3.33 B |  Britain |
 |
ClearPoint Neuro
CLPT
|
-0.9 | $ 11.37 | 1.7 % | $ 322 M | USA |
 |
Cardiovascular Systems
CSII
|
-0.94 | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-0.13 | $ 0.61 | 0.36 % | $ 38 M | USA |
 |
Invacare Corporation
IVC
|
-0.54 | - | - | $ 24.7 M | USA |
 |
IRIDEX Corporation
IRIX
|
-0.26 | $ 1.03 | - | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.43 | - | 14.99 % | $ 929 K | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-1.69 | $ 15.65 | 3.92 % | $ 367 M | USA |
 |
Butterfly Network
BFLY
|
-0.34 | $ 5.4 | 12.97 % | $ 1.14 B | USA |
 |
GBS
GBS
|
-2 | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
-6.16 | $ 2.41 | 14.22 % | $ 6.68 M | USA |
 |
Globus Medical
GMED
|
3.98 | $ 91.34 | 1.29 % | $ 12.4 B | USA |
 |
TransMedics Group
TMDX
|
5.6 | $ 100.01 | -0.77 % | $ 3.4 B | USA |
 |
NanoVibronix
NAOV
|
-26.7 | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
1.52 | $ 36.8 | 0.38 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
2.96 | $ 84.03 | -5.06 % | $ 2.92 B | USA |
 |
Stryker Corporation
SYK
|
2.21 | $ 294.73 | -6.47 % | $ 113 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.84 | $ 83.98 | 0.57 % | $ 49.1 B | USA |
 |
Tandem Diabetes Care
TNDM
|
-0.01 | $ 19.41 | -0.61 % | $ 1.32 B | USA |
 |
LENSAR
LNSR
|
-2.87 | $ 5.61 | 7.27 % | $ 67.1 M | USA |
 |
Pulmonx Corporation
LUNG
|
-1.33 | $ 1.35 | 5.47 % | $ 54.9 M | USA |
 |
MiMedx Group
MDXG
|
0.33 | $ 3.68 | 9.52 % | $ 544 M | USA |
 |
Myomo
MYO
|
-0.37 | $ 0.9 | 4.16 % | $ 37.7 M | USA |